Abstract
Coronavirus disease 2019 (COVID-19) results from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A severe respiratory distress syndrome requiring tracheal intubation develops in approximately 15% to 20% of hospitalized patients with COVID-19, and the mortality rate in these patients can exceed 70%. The extensive use of extracorporeal membrane oxygenation (ECMO) in COVID-19–associated acute respiratory distress syndrome (ARDS) during the pandemic's first wave indicated unfavorable outcomes, raising questions about its usefulness.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
